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Abstract
Background: High platelet reactivity (HPR) during therapy with acetylsalicylic acid (ASA) is a poor prognostic factor in acute 
coronary syndromes (ACS). The prevalence of HPR during ACS is greater than that reported in stable diseases. However, it is 
unclear whether this prevalence of HPR is a transient phenomenon or a characteristic of this high-risk population.
Objective: The main objective is to compare the effects of ASA on platelet function in the initial and late phases of ACS 
in a single population. Secondary objectives are: correlation between the tests between themselves and the relationship 
between the tests and the variation of the inflammatory markers (C-reactive protein and interleukin-6).
Methods: Seventy patients with non-ST segment elevation (NSTE) ACS in use of 100-200 mg of ASA per day for at least 
7 days were prospectively studied. Platelet function was assessed in the first 48 hours and subsequently after 3 months 
using four methods: VerifyNow™ (VFN), whole blood platelet aggregation (WBPA) with arachidonic acid (AA) and collagen 
as agonists, and platelet function analyzer (PFA). The level of statistical significance considered was < 0.05.
Results: According to the more specific methods (WBPA with AA and VFN), the incidence of HPR was significantly higher 
in the early phase than in the late phase: WBPA with AA: 31% versus 13%, p = 0.015; VFN: 32% versus 16%, p = 0.049. 
The other methods tested, which were less specific for ASA, did not show significant differences between phases. 
The correlation between the methods was weak or moderate (r ranging from 0.3 to 0.5, p < 0.05), and there were no 
significant associations between HPR and inflammatory markers.
Conclusion: The prevalence of HPR during AAS therapy, assessed by specific methods for cyclooxygenase 1 (COX-1), is 
higher during the acute phase than in the late phase of NSTE ACS. (Arq Bras Cardiol. 2019; 113(3):357-363)
Keywords: Acute Coronary Syndrome; Platelet Aggregation/drug effects; Myocardial Ischemia; Aged; aspirin/therapeutic 
use; Aspirin/adverse effects.
Introduction
Acetylsalicylic acid (ASA) is widely used as first-line 
antiplatelet therapy for acute coronary syndromes (ACS) 
and is recommended by the guidelines of the American 
Heart Association and the American College of Cardiology,1 
European Society of Cardiology2 and the Brazilian Society of 
Cardiology3 for patients with non-ST segment elevation acute 
coronary syndromes (NSTE ACS).
AAS has been tested with proven efficacy in several 
randomized clinical trials across the spectrum of both acute 
and chronic coronary artery disease.4-7 However, some 
studies have demonstrated high variability in the individual 
antiplatelet response to ASA in different populations and 
scenarios.8 This variability may contribute, at least in part, 
to the high rate of recurrence of ischemic events in patients 
with coronary artery disease.9,10
The prevalence of high platelet reactivity (HPR) in patients 
using ASA depends, among other factors, on the laboratory 
test and cut-off point used, as well as on the clinical picture. 
In patients with chronic arterial disease, the prevalence ranges 
from 0 to 57% (24%, on average).10-13 More importantly, 
patients with HPR have been described to have a poorer clinical 
outcome, with a higher incidence of serious cardiovascular 
events, including mortality.10,11,14
In ACS, the estimated prevalence of HPR is supposedly 
higher.15 Previous studies have suggested that atherosclerotic 
load and systemic inflammation may have a significant 
influence on platelet reactivity.16,17 However, it is not clear 
whether this high prevalence of HPR is a transient acute 
phase phenomenon or a permanent characteristic of this 
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high risk population, since, to the best of our knowledge, 
no study has analyzed the response to ASA during 
the acute and chronic phases in the same population. 
The present study was designed to give a definitive answer 
on this important question.
Methods
Study population
Prospective inclusion of 70 consecutive patients admitted 
to the emergency department (ED) of a tertiary cardiology 
hospital with a diagnosis of NSTE ACS, with initial evaluation 
at admission (acute phase) and subsequently 3 months after 
discharge (late phase). Patients were considered eligible for 
inclusion if aged ≥ 18 years, had been diagnosed with unstable 
angina or non-ST segment elevation myocardial infarction 
within the first 48 hours of clinical onset, and were using 
100 mg to 200 mg of AAS for at least 7 days prior to the event.
The main exclusion criteria were the use of another 
antiplatelet agent in addition to ASA, oral or parenteral 
anticoagulation, percutaneous coronary intervention (PCI) in 
the last 30 days or myocardial revascularization surgery in the last 
90 days. Other exclusion criteria were hemoglobin < 10 g/dL; 
platelets < 100,000/mm3 or > 500,000/mm3; creatinine 
clearance < 30 mL/min; decompensated heart failure (Killip III 
or IV); current use of inotropes or vasopressors; and known 
hematological or neoplastic diseases.
Model
Patients were evaluated at two different moments: initially, 
at admission to ED, prior to the administration of any other 
antithrombotic treatment except ASA, and 3 months after 
hospital discharge, when they should also be on ASA as the 
only antiplatelet agent. At each evaluation, patients were 
evaluated and interviewed, and underwent blood collection 
1 to 4 hours after the use of ASA. Adherence to ASA treatment 
was systematically evaluated during face-to-face medical 
interviews. The study is in accordance with the Helsinki 
Declaration and was approved by the local Ethics Committee; 
patients provided their informed consent.
Objectives
The primary objective of the study was to compare platelet 
aggregation in patients with NSTE ACS in the acute phase 
(the first 48 hours of the clinical picture) in relation to the 
late phase (3 months after) using four different methods of 
evaluating platelet aggregation: VerifyNow™ aspirin (VFN) 
(Accumetrics, Inc., San Diego, California, USA); whole blood 
platelet aggregation (WBPA) using arachidonic acid (AA) 
(Sigma-Aldrich, Saint Louis, Missouri, USA) and collagen 
(Chrono-Log®; Chrono-Log Co., Havertown, Pennsylvania, 
USA); PFA-100® Platelet Function Analyzer with collagen/ADP 
cartridge (COL/EPI) (Siemens Healthcare Diagnostics, Newark, 
Delaware, USA). Secondary objectives were the correlation 
between the four tests in the acute phase and the relationship 
between each of the tests with inflammatory markers 
(C-reactive protein and interleukin-6).
Blood collection
All blood samples were collected through antecubital 
venous puncture with a 21 gauge needle between 10:00 am 
and 1:00 pm. The four tests were performed within two hours 
of the collection.
Definition of HPR
The cut-off values used to define HPR were: PFA-100®, 
closure time (CT) < 150 seconds;18 VFN, aspirin reaction units 
(ARU) ≥ 550 (according to the manufacturer); WBPA with AA, 
Ω ≥ 3;19 WBPA with collagen, Ω ≥ 10.20
Statistical analysis
The sample size was calculated based on the expected 
mean result of the PFA-100® test, which was 191 seconds ± 
10021 during the acute phase, and the 25-second reduction 
estimate of that value in the chronic phase. According to 
the McNemar test, with 80% power and alpha of 0.05, 
70 patients were required. The continuous variables were 
evaluated for their distribution (Gaussian or not) using the 
Kolmogorov-Smirnov test.
Parametric continuous variables were presented as 
mean ± standard deviation, and nonparametric variables 
as medians and interquartile ranges (25-75). The unpaired 
Mann-Whitney (non-Gaussian variables) or Student’s T 
(Gaussian variables) tests were used with the Welch 
correction when indicated. When comparing two different 
moments, the Wilcoxon test was used for the non-Gaussian 
variables and the paired Student’s T for Gaussian samples. 
The categorical variables were presented in relative and 
absolute frequencies. Contingency distribution tables were 
analyzed using the chi-square test and Fisher’s exact test. 
Analysis of the correlation between the tests was done with 
Spearman's correlation coefficient. Values of p < 0.05 were 
considered statistically significant. The software used was 
SPSS (IBM Corporation), version 11.
Results
Patients’ characteristics
The demographic and baseline characteristics of the 
patients are summarized in Table 1. Almost half of the 
patients reported a previous history of diabetes. The majority 
(64%) had a classification for thrombolysis in myocardial 
infarction (TIMI) with risk for non-ST segment elevation ACS 
equal to 3 or 4 on admission. All patients were on 100 to 
200 mg ASA as the only antiplatelet agent in the last 7 days 
prior to the collection of the tests, both in the acute phase 
and in the late phase.
Primary objective
Platelet aggregation tests were divided into COX-1-specific 
(WBPA with AA and VFN) and COX-1-nonspecific (WBPA 
with collagen and PFA-100®). COX-1-specific tests were 
associated with higher platelet reactivity in the acute phase, 
compared to the late phase (Figure 1). Comparisons between 
the phases by the nonspecific COX-1 tests did not show 
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Table 1 – Demographic and baseline characteristics of patients
Number of patients 70
Age, years (mean ± SD) 64.2 ± 9.7
Female, n (%) 38 (54.3)
Medical history
Diabetes mellitus, n (%) 34 (48.6)
Hypertension, n (%) 61 (87.1)
Dyslipidemia, n (%) 58 (82.9)
Current smoking, n (%) 11 (15.7)
Obesity, n (%) 16 (22.9)
Family history of CAD, n (%) 28 (40)
AMI, n (%) 41 (58.6)
SMR or PCI, n (%) 38 (54.3)
CHF, n (%) 6 (8.6)
Type of ACS
Unstable angina, n (%) 54 (77.1)
NSTE AMI, n (%) 16 (22.9)
TIMI risk score
0 to 2, n (%) 15 (21)
3 to 4, n (%) 45 (64)
≥ 5 (%) 10 (15)
Previously used medications
PPIs, n (%) 32 (45.7)
Beta-blockers, n (%) 55 (78.6)
Calcium channel blockers, n (%) 10 (15)
ACEIs/ARBs, n (%) 45 (64.3)
Aldosterone antagonists, n (%) 3 (4.3)
Laboratory tests Median (25th/75th)
Hemoglobin, g/dL 13.7 (12.8/14.7)
Leukocytes × 1.000/mm3 8.0 (6.5/9.2)
Platelets × 1.000/mm3 220 (179/273)
Creatinine, g/dL 1.0 (0.9/1.2) 
ARBs: angiotensin receptor blockers; SMR: Surgical myocardial 
revascularization; CAD: coronary artery disease; AMI: acute myocardial 
infarction; PPIs: proton pump inhibitors; CHF: congestive heart failure; 
PCI: percutaneous coronary intervention; ACEIs: angiotensin converting 
enzyme inhibitors; ACS: acute coronary syndrome; NSTE: non-ST segment 
elevation; TIMI: thrombolysis in myocardial infarction.
significant differences (PFA = 215.9 ± 83.75 seconds versus 
200.51 ± 84.63 seconds, respectively, in the acute and late 
phases, p = 0.233; WBPA with collagen, 7.19 ± 5.64 Ω versus 
6.46 ± 5.09 Ω, p = 0.658).
When the results were categorized according to 
pre-established cutoff values for HPR diagnosis (Table 2), 
COX-1-specific tests were associated with significant 
differences between the acute and late phases (WBPA with 
AA, 31.4% versus 12.8%, p = 0.015; VFN, 32.1% versus 16%, 
p = 0.049), whereas nonspecific tests did not show significant 
differences (PFA, 34.2% versus 40%, p = 0.50; WBPA with 
collagen, 33.8% versus 30.8%, p = 0.86).
Secondary objectives
Correlation between platelet tests
In the acute phase, the analyzed methods correlated 
significantly (Table 3). However, the magnitude of this 
correlation was only moderate (r > 0.4) between WBPA with 
AA and WBPA with collagen. The correlation between the 
other methods was only weak (r > 0.2 and < 0.4).
Variation of inflammatory markers and platelet reactivity 
between acute and late phases
C-reactive protein (CRP) levels differed significantly between 
the acute and late phases [median CRP = 2.84 mg/dL (1.54 to 
8.41) versus 1.41 mg/dL (0.73 to 5.64), p = 0.006], whereas 
interleukin-6 (IL-6) did not differ between the two phases 
[median IL-6 = 2.1 pg/mL (2.0 a 5.68) versus 2.0 pg/mL (2.0 
to 3.25), p = 0.110]. When CRP (acute/late) variation was 
compared to the variation of the methods in the two phases 
analyzed, a weak but significant correlation (Figure 2) was 
demonstrated between CRP and VFN (r = 0.29, p= 0.03).
Discussion
Our data demonstrate significant differences in response to 
ASA during the acute and late phases of acute coronary disease.
Previous studies have unequivocally documented that ASA 
reduces the occurrence of cardiovascular events in patients 
with CAD.4-7 Even with the advent of the new antiplatelet 
agents that act by blocking the P2Y12 receptor, the role of 
ASA remains unchanged as it is considered, in all guidelines, 
a routine treatment in this population.1-2 However, it has been 
well established that there is significant variability in residual 
platelet function during ASA therapy, especially in the context 
of ACS, in which the prevalence of HPR is more evident.8,17 
The reason for this variability is not fully understood. 
One hypothesis is that HPR is present in a subpopulation 
of patients with chronic CAD, leading to a decrease in 
the efficacy of ASA and, as a consequence, increasing the 
likelihood of developing ischemic cardiovascular events. 
Another hypothesis is that HPR develops during the acute 
ischemic episode, as a consequence of the increase in platelet 
reactivity due to phenomena occurring in the acute phase 
(increased inflammatory activity, increased rate of platelet 
renewal, activation of the coagulation system, among others).
To our knowledge, this study was the first to test both 
hypotheses in the same population of patients with NSTE ACS. 
Our results showed that, for most patients, HPR is labile, with a 
higher prevalence observed during the acute phase compared 
to the late phase. These results are consistent with the data 
reported by Hobikoglu et al.,21 who analyzed two different 
populations (one group of patients hospitalized with ACS and 
another group of patients with chronic CAD).
The present demonstrations can have a significant 
therapeutic impact, since approximately one third of our 
patients showed HPR during the initial phase of ACS, and 
new regimens, including change of dosage and use of more 
potent antiplatelet agents, may be proposed to reduce the risk 
of ischemic events. Neubauer et al.22 evaluated a therapeutic 
regimen of dose escalation of ASA and clopidogrel in 
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Figure 1 – Comparison of COX-1-specific tests (WBPA with AA and VFN) between the acute and late phases. WBPA: whole blood platelet aggregation; AA: arachidonic 
acid; VFN: VerifyNow™; URA: units of reaction to acetylsalicylic acid.
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Table 2 – Comparison of HPR by different platelet tests between the acute and late phases
Test
Acute Phase Late Phase
p
HPR HPR
PFA 34.2% 40% 0.503
WBPA with AA 31.4% 12.8% 0.015
VFN 32.1% 16% 0.049
WBPA with Col 33.8% 30.8% 0.860
WBPA: whole blood platelet aggregation; AA: arachidonic acid; Col: collagen; PFA: Platelet Function Analyzer (PFA-100®); VFN: VerifyNow™; p: p value.
Table 3 – Correlation between platelet tests in the acute phase
WBPA with AA WBPA with Col VFN
PFA rs –0.429* –0.281* –0.279*
WBPA with AA rs 0.498* 0.393*
WBPA with Col rs 0.318*
* p < 0.05, AA: arachidonic acid; Col: collagen; WBPA: whole blood platelet aggregation; PFA: PFA-100®; rs: Spearman correlation coefficient; VFN: VerifyNow™.
patients with ACS or unstable angina undergoing PCI and 
considered nonresponders by WBPA with AA and adenosine 
diphosphate (ADP). Patients considered nonresponders to 
ASA were treated with increasing doses of 100 mg to 300 mg 
per day, and up to 500 mg, if necessary, with improved 
therapeutic response.
On the other hand, our data demonstrate that, although 
there is a significant decrease in the incidence of HPR during 
the chronic phase, a significant percentage of the population 
still present HPR at this stage.
The high rate of platelet turnover that occurs in 
several situations (including ACS) could be one of the 
explanations for our findings; however, this mechanism 
was not analyzed in the present study. As demonstrated in 
previous studies in diabetic patients in the postoperative 
period of cardiac surgery,23-25 the number of circulating 
immature platelets increases as a consequence of increased 
platelet consumption, leading to an exponential increase 
in the platelet turnover rate. In a study by Dillinger et al.,26 
comparing different doses of ASA twice daily in diabetic 
patients with CAD and at least one risk factor, twice daily use 
of the drug reduced HPR rate when compared to the same 
dose administered once a day. However, in the CURRENT 
study, the use of a double dose of ASA showed no benefit 
when compared to the conventional dose.27
Another possibility would be the influence of the 
inflammatory process, which is characteristic of the acute phase, 
on platelet function, resulting in increased platelet activation and 
increased HPR in response to ASA. In the present study, there 
was a significant but weak association between inflammation 
and platelet reactivity, analyzed by PCR and VNF, respectively 
(r = 0.293, p = 0.03). In a stable CAD population, Bernlochner 
et al.28 showed a significant, positive and independent 
association between CRP levels and platelet aggregation, which 
were assessed by WBPA with ADP. Similarly, Tantry et al.29 
reported a significant correlation between inflammatory markers 
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Figure 2 – Correlation between the variation of CRP and VFN (acute/late). CRP: C-reactive protein; VFN: VerifyNow™; r: Spearman’s coefficient.
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(including CRP), markers of hypercoagulability and platelet 
function in different CAD spectra (asymptomatic, stable CAD 
and ACS). However, contrary to these findings, Ziegler et al.30 
demonstrated that in patients with peripheral arterial disease, 
there was no significant correlation between CRP and platelet 
aggregation measured by PFA-100®. These conflicting results 
can be attributed, at least in part, to methodological differences.
In our study, different methods of determining platelet function 
were used simultaneously. The correlation between the tests 
during the acute phase was significant, but the magnitude of 
these correlations was only weak or moderate. Unexpectedly, 
even the methods classified as COX-1-specific showed medium 
to low correlation with each other. These findings are consistent 
with findings from previous studies: Lordkipanidzé et al.19 studied 
201 patients with stable CAD undergoing aspirin therapy19 using 
six different tests. The prevalence of HPR varied from 4% when 
analyzed by optical aggregometry with AA, to 59.5%, when 
analyzed by PFA-100® (COL/EPI). In this study, as in ours, there 
were weak correlations between methods for determining platelet 
function, including COX-1 specific methods. The present study 
was the first to analyze different methods of platelet aggregation 
during the acute and late phases, in the same population of 
patients with NSTE ACS.
In summary, our findings may have important therapeutic 
implications in demonstrating that one-third of the patients 
showed HPR in the acute phase, leading to the hypothesis 
that new dosing regimens should be tested in this population. 
In addition, despite the fact that there is a significant decrease 
in the incidence of HPR during the chronic phase, a significant 
percentage of the population still presents HPR at this stage.
Study limitations
Firstly, our study had a relatively small sample size, but it 
was adequate to assess the primary outcome. However, the 
secondary results should be considered as hypothesis generators 
and interpreted with caution. Secondly, all patients were on 
chronic ASA use at a dose of 100 mg/day to 200 mg/day, but 
individual doses were not collected and may have influenced 
the results obtained.25 Lastly, in recent times, the role of young 
(immature) platelets has been valued; if they had been assessed 
in the present study (which was not done), they could have 
added important information.
Conclusion
In conclusion, the prevalence of HPR during ASA therapy 
measured by COX-1-specific methods is higher during the 
acute phase than in the late phase of patients with non-ST 
segment elevation ACS. However, the relationship between 
inflammation as indicated by CRP and IL-6 and platelet reactivity 
in these two phases is weak, suggesting that the variability in the 
inflammation state may not play a role in the temporal changes 
in platelet reactivity in this population.
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